Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Against a backdrop of growing demand for generic drugs, supply concerns, and soaring energy and raw material prices, the company is working to improve production efficiency and its supply structure, reflect higher costs in selling prices, and expand its product lineup.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥51,622 million (YoY +4.3%) |
| Operating profit | ¥4,953 million (YoY -29.0%) |
| Ordinary income | ¥4,445 million (YoY -34.7%) |
| Profit attributable to owners of the parent | ¥2,429 million (YoY -50.3%) |
| Net income per share | ¥21.04 |
| Equity ratio | End of the current fiscal period 48.1% / End of previous period 49.6% |
| Total assets | ¥368,979 million |
| Net assets | ¥177,653 million |
| Cash flows from operating activities | ¥-427 million |
| Cash flows from investing activities | ¥-12,706 million |
| Cash flows from financing activities | ¥10,197 million |
| Cash and cash equivalents at end of period | ¥26,059 million |
| Full-year earnings forecast | Net Sales ¥208,400 million (YoY +3.3%) / Operating profit ¥27,200 million (YoY +71.1%) / Ordinary income ¥26,000 million (YoY +82.2%) / Net income ¥18,600 million (YoY +78.2%) |
| Annual Dividend Forecast | ¥55.00 → ¥56.00 |
| Segment revenue | Segment Manufacture and sale of pharmaceuticals and related products / Net Sales ¥51,622 million / Year on year against the same period last year 4.3 |
| Depreciation and amortization | ¥4,347 million |
| Impairment loss | ¥525 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | Change No / New Not disclosed / Excluded Not disclosed / Company name Not disclosed |
| Material subsequent events | On 30 July 2026, the company issued its fourth unsecured corporate bond, a social bond. The total issue amount was ¥10 billion, the annual interest rate was 3.441%, and the maturity date is 30 July 2036. The proceeds are scheduled to be used to fund capital investment related to expanding the production capacity of トラストファーマテック. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (online, for institutional investors and analysts) |
| Issued Shares at Period-End | 115,487,137 Shares |
| Treasury Shares at Period-End | 1,503 Shares |
| Factors Behind Changes in Business Performance | Against a backdrop of growing demand for generic drugs, supply concerns, and soaring energy and raw material prices, the company is working to improve production efficiency and its supply structure, reflect higher costs in selling prices, and expand its product lineup. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited the growing demand for generic drugs, supply concerns, and surging energy and raw material prices as key factors in the business environment. It said it is working to improve production efficiency and its supply structure, reflect higher costs in selling prices, and expand its product lineup. However, it did not provide a monetary breakdown of the factors behind the decline in quarterly profit.